title: Single, high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double-blind study.
abstract: Effective and less toxic treatments are needed for patients with severe, steroid-dependent asthma. Both low-dose oral methotrexate and high-dose intramuscular triamcinolone have been recommended for these patients. We compared the effects of these two medications on pulmonary function, peak flow rates, airway reactivity, oral steroid use, emergency room (ER) visits, and hospitalizations in patients with steroid-dependent, life-threatening asthma. In a randomized, placebo-controlled, double-blind study, we investigated 19 such patients. Six of the patients (Group I) received a single dose of 360 mg triamcinolone intramuscularly with placebo methotrexate; seven patients (Group II) received placebo triamcinolone followed by low-dose oral methotrexate (a first dose of 7.5 mg followed by 15 mg weekly); and six patients (Group III) received placebo triamcinolone with placebo methotrexate. All patients used the same high-dose inhaled steroids. The patients took tapering courses of oral steroids when needed, but attempted to reduce their oral steroid use whenever possible. Methacholine challenge testing was performed every 6 wk, pulmonary function tests every 4 wk, and home peak-flow measurements twice daily. Oral steroid use, ER visits, and hospitalizations were also monitored. The patients in the triamcinolone treatment group showed a significant and sustained increase in home peak-flow rates, and their FEV1 persistently improved by a mean of 40% (p < 0.05), whereas the FEV1 of the patients in the methotrexate treatment and placebo groups remained near baseline. The PC20 in the triamcinolone group increased progressively (p > 0.05), and the improvements in total mean reactivity were greater in this group than in either of the other two groups (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York 10467-2490, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Ogirala
authors.forename: T M
authors.initials: TM
authors.lastname: Sturm
authors.forename: T K
authors.initials: TK
authors.lastname: Aldrich
authors.forename: F F
authors.initials: FF
authors.lastname: Meller
authors.forename: E B
authors.initials: EB
authors.lastname: Pacia
authors.forename: A M
authors.initials: AM
authors.lastname: Keane
authors.forename: R I
authors.initials: RI
authors.lastname: Finkel
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests / Q000706:statistics & numerical data; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D018927:Anti-Asthmatic Agents; D014222:Triamcinolone Acetonide; D008727:Methotrexate